LUPIN : RECEIVES US FDA APPROVAL FOR AMIFAMPRIDINE TABLETS

• US FDA approves Lupin's ANDA for Amifampridine Tablets, 10 mg • Product is bioequivalent to reference listed drug Firdapse Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc. • Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity • Approval adds to Lupin's US generics portfolio across its core therapeutic areas

Lupin Ltd

Open attachment

← Back to feed